3692 — Hansoh Pharmaceutical Share Price
0.000.00%
Last trade - 00:00- HK$112.51bn
- HK$87.43bn
- CNY10.10bn
- 99
- 25
- 91
- 86
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 26.51 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -3.2% | ||
| Dividend Yield (f) | 1.17% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.76 | ||
| Price to Tang. Book | 3.79 | ||
| Price to Free Cashflow | 24.94 | ||
| Price to Sales | 8.67 | ||
| EV to EBITDA | 17.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 19.3% | ||
| Return on Equity | 18.1% | ||
| Operating Margin | 45.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 8,682.75 | 8,690.23 | 9,935.14 | 9,382.41 | 10,103.81 | 12,071.84 | 12,670.66 | 5.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +26.59 | -6.41 | +1.11 | -1.77 | +25 | +26.91 | -3.2 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.
Directors
- Huijuan Zhong CHM (60)
- Rudi Bao SVP (57)
- Gongzheng Wu SVP (50)
- Chuanhe Xu SVP (57)
- Chunhua Zhong SVP (46)
- Shengli Zhong VPR (53)
- Min Hu VPR (44)
- Aifeng Lyu EDR (44)
- Yuan Sun EDR (34)
- Yan Wing Li SEC
- Sheung Wai Chan NID (67)
- Guoqiang Lin NID (78)
- Dongtao Yang NID (63)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 2nd, 2015
- Public Since
- June 14th, 2019
- No. of Employees
- 9,099
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 5,934,335,005
- Address
- 287 Xiangke Road, Pudong New District, SHANGHAI, 201210
- Web
- https://www.hspharm.com/
- Phone
- Auditors
- Ernst & Young CPA
Upcoming Events for 3692
Hansoh Pharmaceutical Group Company Ltd Annual Shareholders Meeting
Half Year 2025 Hansoh Pharmaceutical Group Company Ltd Earnings Release
Similar to 3692
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Hansoh Pharmaceutical share price?
As of Today at 02:01 UTC, shares in Hansoh Pharmaceutical are trading at HK$18.96. This share price information is delayed by 15 minutes.
How has the Hansoh Pharmaceutical share price performed this year?
Shares in Hansoh Pharmaceutical last closed at HK$18.96 and the price had moved by +26.06% over the past 365 days. In terms of relative price strength the Hansoh Pharmaceutical share price has outperformed the FTSE Developed Asia Pacific Index by +33.24% over the past year.
What are the analyst and broker recommendations for Hansoh Pharmaceutical?
The overall consensus recommendation for Hansoh Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Hansoh Pharmaceutical dividend yield?
The Hansoh Pharmaceutical dividend yield is 1.79% based on the trailing twelve month period.
Does Hansoh Pharmaceutical pay a dividend?
Last year, Hansoh Pharmaceutical paid a total dividend of CNY0.32, and it currently has a trailing dividend yield of 1.79%. We do not have any data on when Hansoh Pharmaceutical is to next pay dividends.
When does Hansoh Pharmaceutical next pay dividends?
We do not have data on when Hansoh Pharmaceutical is to next pay dividends. The historic dividend yield on Hansoh Pharmaceutical shares is currently 1.79%.
How do I buy Hansoh Pharmaceutical shares?
To buy shares in Hansoh Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hansoh Pharmaceutical?
As of the previous close price of HK$18.96, shares in Hansoh Pharmaceutical had a market capitalisation of HK$112.51bn.
Where are Hansoh Pharmaceutical shares listed?
Here are the trading details for Hansoh Pharmaceutical:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 3692
What kind of share is Hansoh Pharmaceutical?
Based on an overall assessment of its quality, value and momentum Hansoh Pharmaceutical is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hansoh Pharmaceutical share price forecast for 2025?
The analyst consensus target price for shares in Hansoh Pharmaceutical is HK$23.71. That is 25.07% above the last closing price of HK$18.96.
Analysts covering Hansoh Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of CNY0.69 for the next financial year.
Find out moreWhat is the trend in the Hansoh Pharmaceutical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hansoh Pharmaceutical. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +3.76%.
As of the last closing price of HK$18.96, shares in Hansoh Pharmaceutical were trading +4.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hansoh Pharmaceutical PE Ratio?
The Hansoh Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 26.51. The shares last closed at HK$18.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hansoh Pharmaceutical?
Hansoh Pharmaceutical's management team is headed by:
- Huijuan Zhong - CHM
- Rudi Bao - SVP
- Gongzheng Wu - SVP
- Chuanhe Xu - SVP
- Chunhua Zhong - SVP
- Shengli Zhong - VPR
- Min Hu - VPR
- Aifeng Lyu - EDR
- Yuan Sun - EDR
- Yan Wing Li - SEC
- Sheung Wai Chan - NID
- Guoqiang Lin - NID
- Dongtao Yang - NID